Tag: GlobeNewswire

Two-year extension builds on productive relationship established in 2019

Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States

BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and Gilead Sciences have agreed to extend the research term for an undisclosed oncology program within the companies’ ongoing strategic collaboration by an additional two years. This is the second two-year extension of the research term for this program.  

“Gilead’s decision to extend the research term for this program reflects our longstanding commitment to productive collaborations, the outstanding dedication of our research teams, and the potential of Nurix’s targeted protein degradation platform to generate novel medicines against therapeutically important targets,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix. “Our collaboration has already advanced GS-6791, an oral IRAK4 degrader discovered by Nurix, into clinical development, and we are pleased to continue working with Gilead to discover and advance additional drug candidates across oncology and inflammatory diseases. This extension provides further evidence of the value of the collaboration and the capabilities of our platform.”

Under the collaboration agreement, originally established in 2019, Nurix is deploying its proprietary drug discovery platform to identify novel agents that use E3 ligases to induce degradation of specified drug targets. Gilead has an option to license drug candidates resulting from the collaboration, and Nurix retains options for 50/50 profit and loss sharing for development, commercialization, and co-detailing on up to two programs in the United States, subject to certain restrictions. For programs in which Nurix exercises its option, the parties will share U.S. development costs as well as profits and losses 50/50, and Nurix will be eligible to receive royalties on ex-U.S. sales and reduced milestone payments.

In connection with today’s announcement, Nurix will receive a $10 million research term extension fee under the amended collaboration agreement. As of May 31, 2026, Nurix is eligible to receive up to approximately $1.3 billion in total payments based on certain additional fees, payments and the successful completion of certain preclinical, clinical, development and sales milestones. Nurix is also eligible to receive mid-single-digit to low-teens percentage tiered royalties on annual net sales from any commercial products. The first program licensed by Gilead under this agreement, GS-6791 (NX-0479), is a potent, selective, oral IRAK4 degrader which is now in Phase 1 clinical development.

About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical-stage oncology pipeline includes bexobrutideg, a degrader of BTK being co-developed with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix’s autoimmune disease pipeline includes bexobrutideg in collaboration with Roche and clinical-stage degraders of IRAK4 in collaboration with Gilead and STAT6 in collaboration with Sanofi. Nurix is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates in its wholly owned preclinical pipeline and under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information, visit www.nurixtx.com.

Forward-Looking Statements
This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding: Nurix’s expectations for its collaboration with Gilead Sciences; the potential benefits of Nurix’s collaboration with Gilead Sciences; the potential benefits of the research term extension for the undisclosed oncology program; the potential achievement of milestone, royalty and license payments; and the potential advantages of Nurix’s scientific approach and DEL-AI platform. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions. Although Nurix believes such expectations and assumptions are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) the ability of each party to perform its obligations under the Nurix-Gilead collaboration; (ii) whether the parties will be able to successfully conduct and complete preclinical development, clinical development and commercialization of any drug candidates under the Nurix-Gilead collaboration; (iii) the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development; (iv) whether Nurix will be able to fund development activities and achieve development goals, including those under the Nurix-Gilead collaboration; (v) risks and uncertainties relating to the timing and receipt of payments from Nurix’s collaboration partners, including milestone payments and royalties on future potential product sales; and (vi) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal period ended May 31, 2026, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.

Contacts:
Media and Investors
Kris Fortner
Nurix Therapeutics, Inc.
ir@nurixtx.com

First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface Franchise

NASHVILLE, Tenn., Oct. 05, 2026 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has closed its previously announced acquisition of TYRVAYA^® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. At closing, Harrow acquired worldwide rights to TYRVAYA, except for Japan. Viatris retained the rights to commercialize TYRVAYA in Japan and agreed to pay Harrow royalties on any future net sales there. Consistent with the terms announced in August, Harrow paid $30 million in cash at closing and may pay up to $70 million in contingent milestone payments tied to TYRVAYA’s net sales, for potential total consideration of up to $100 million. The closing payment was funded with cash on hand.

TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is the first and only FDA-approved nasal spray for DED. Unlike topical ophthalmic therapies, TYRVAYA is administered through the nose and is thought to activate the trigeminal parasympathetic pathway to stimulate basal tear production. TYRVAYA is approved in the U.S., China, and Taiwan, with marketing applications pending in additional markets.

The addition of TYRVAYA meaningfully expands Harrow’s position in the large and growing U.S. dry eye market and complements VEVYE^®, Harrow’s flagship prescription therapy for DED. With two highly differentiated branded prescription products, Harrow believes it can give eyecare professionals greater flexibility to individualize treatment based on their patients’ needs and preferences.

“Today marks an important step forward for Harrow and for the physicians and patients we serve,” said Mark L. Baum, Chief Executive Officer of Harrow. “Dry eye disease is complex and multifactorial, and there is no single treatment approach that works for every patient. VEVYE and TYRVAYA approach dry eye differently and give eyecare professionals two distinct tools from one organization committed to serving this market. VEVYE remains the cornerstone of our dry eye franchise, while TYRVAYA gives us an established, complementary prescription brand with a unique route of administration and an existing base of physicians who know and use the product.”

Baum added, “We see a significant commercial opportunity ahead. TYRVAYA comes to Harrow with meaningful physician awareness, an established prescription base, and years of real-world clinical experience. By combining that foundation with Harrow’s expanding Ocular Surface commercial organization, market access capabilities, and focus on patient access and affordability, we believe we can introduce TYRVAYA to many more eyecare professionals and patients while also expanding awareness of VEVYE among existing TYRVAYA prescribers.”

Expanding Harrow’s Ocular Surface Commercial Platform

TYRVAYA will be available to eyecare professionals through Harrow’s commercial organization immediately after closing. As part of the acquisition, Harrow expects approximately 40 experienced personnel from Viatris, with established knowledge of TYRVAYA and the dry eye market, to join and augment Harrow’s existing Ocular Surface commercial team. Harrow expects to onboard these new colleagues during the fourth quarter of 2026. Harrow’s expanded Ocular Surface team will support both VEVYE and TYRVAYA as the integration progresses.

Harrow believes the combination of two differentiated dry eye brands and a larger, experienced field organization create several attractive commercial opportunities:

• Expanded prescriber reach: The approximately 40 personnel expected to join Harrow will materially increase the size of Harrow’s Ocular Surface team, expanding its reach and frequency of engagement with ophthalmologists and optometrists who manage dry eye disease.
• Broader portfolio engagement: TYRVAYA brings an established prescriber base and meaningful familiarity among eyecare professionals. Bringing VEVYE and TYRVAYA together creates opportunities to deepen engagement across both brands and expand utilization across Harrow’s dry eye portfolio.
• Commercial efficiency: Both VEVYE and TYRVAYA utilize PhilRx as their primary specialty pharmacy and will be supported by a single Ocular Surface commercial organization, allowing Harrow to leverage shared commercial, market access, patient-support, and operational infrastructure across both brands.

Harrow expects TYRVAYA to contribute more than $30 million in revenue in 2027. With commercial integration beginning in the fourth quarter of 2026, Harrow believes TYRVAYA’s established prescription base, physician awareness, and experienced commercial team, combined with Harrow’s dedicated Ocular Surface infrastructure, provide a strong foundation for growth in 2027 and beyond.

“TYRVAYA is a product I have used extensively in my dry eye practice, and its nasal route of administration makes it a truly differentiated treatment option,” said Laura Periman, MD, a board-certified ophthalmologist at Periman Eye Institute. “For patients who struggle with eye drops or contact lens wearers who want an option that does not require removing their lenses, TYRVAYA can fit very well into their treatment routine. I have seen firsthand the value of stimulating a patient’s own tear production, and I am pleased to see TYRVAYA become part of Harrow, a company deeply committed to eyecare and patient access.”

“VEVYE has become an important option in my dry eye practice because of the clinical benefits it can provide, and TYRVAYA is another therapy I know well and have prescribed for years,” said Paul Karpecki, OD, Director of Cornea and External Disease at Kentucky Eye Institute. “The two products approach dry eye very differently: VEVYE is applied directly to the ocular surface, while TYRVAYA is administered nasally and stimulates natural tear production through a distinct mechanism. Having therapies with different mechanisms and routes of administration gives me greater flexibility to individualize treatment based on each patient’s needs. I’m pleased to see both products together at Harrow, giving physicians more options for patients with this chronic disease.”

Eyecare professionals can send TYRVAYA prescriptions using their electronic medical record (EMR) software directly to Harrow’s dedicated pharmacy partner, PhilRx. Prescriptions can also be sent to any retail pharmacy. TYRVAYA is fully stocked in the wholesale distribution channel, including McKesson, Cardinal, and Cencora, and can be shipped to any retail pharmacy, generally within 24 hours of order placement.

Interested patients should ask their trusted eyecare professional whether TYRVAYA and VEYVE are right for them.

VEVYE^® (cyclosporine ophthalmic solution) 0.1%

INDICATIONS AND USAGE
VEVYE^® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

Important Safety Information
WARNINGS AND PRECAUTIONS
Potential for Eye Injury and Contamination: To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.

Use with Contact Lenses: VEVYE^® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE^®.

ADVERSE REACTIONS
In clinical trials with 738 subjects receiving at least 1 dose of VEVYE^®, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

Please see full Prescribing Information for VEVYE.

TYRVAYA^® (varenicline solution) nasal spray 0.03 mg

INDICATIONS AND USAGE
TYRVAYA (varenicline solution) nasal spray is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease.

Important Safety Information
ADVERSE REACTIONS
The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5–16% of patients were cough, throat irritation, and instillation-site (nose) irritation.

Please see full Prescribing Information for TYRVAYA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of this acquisition and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such documents may be read free of charge on the SEC’s web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor & Media Contact:
Mike Biega
Vice President of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890

ATLANTA, Oct. 05, 2026 (GLOBE NEWSWIRE) — Americold Realty Trust (NYSE: COLD), a global leader in temperature-controlled logistics, real estate, and value-added services focused on the ownership, operation, acquisition and development of temperature-controlled warehouses, today announced that the Company will release third quarter 2026 financial results before the market opens on Thursday, November 5, 2026. A conference call will be held on Thursday, November 5, 2026 at 8:00 a.m. Eastern Time.

Webcast:

A webcast of the conference call will be available on the Investor Relations section of the Company’s website at www.americold.com. To listen to the live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register and install any necessary audio software.

To Participate in the Telephone Conference Call:

Dial in at least 5 minutes prior to start time:
Domestic: 1-844-826-3035
International: 1-412-317-5195

Conference Call Playback:

Domestic: 1-844-512-2921
International: 1-412-317-6671
Pass code: 10212104
The playback can be accessed through November 19, 2026.

About Americold Realty Trust, Inc.

Americold (NYSE: COLD) is a global leader in temperature-controlled logistics and real estate, with a more than 120-year legacy of innovation and reliability. With more than 220 facilities across North America, Europe, Asia-Pacific, and South America – totaling approximately 1.4 billion refrigerated cubic feet – Americold ensures the safe, efficient movement of refrigerated products worldwide.

Our facilities are an integral part of the global food supply chain, connecting producers, processors, distributors, and retailers with tailored, value-added services supported by responsive and reliable supply chains. Leveraging deep industry expertise, smart technology, and sustainable practices, Americold delivers world-class service that creates lasting value for our customers and the communities we serve. Visit www.americold.com to learn more.

Contacts:

Americold Realty Trust, Inc.
Investor Relations
Telephone: 678-459-1959
Email: investor.relations@americold.com

Also reports 
918.8 m of 0.62% CuEq¹, including 302 m of 0.76% CuEq¹
and
901 m of 0.47% CuEq¹, including 196 m of 0.73% CuEq¹
and
940.7 m of 0.49% CuEq¹, including 165 m of 0.80% CuEq¹
and
841.9 m of 0.54% CuEq¹, including 253 m of 0.73% CuEq¹

VANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) — Aldebaran Resources Inc. (“Aldebaran” or the “Company”) (TSX-V: ALDE, OTCQX: ADBRF) is pleased to provide results from all remaining holes of the 2025-2026 infill and geotechnical drilling program at the Altar project in San Juan, Argentina. The drilling program was designed to upgrade Inferred resources to the higher-confidence Measured and Indicated categories while also supporting geotechnical studies. Several of the holes reported today were drilled exclusively for geotechnical purposes in final pit wall areas where significant mineralization was not expected.

Highlights

ALD-26-260

• 1,728.90 m of 0.45% CuEq¹ from 141.00 m depth
  • Including 1,427.90 of 0.52% CuEq¹ from 442.00 m depth
    • Including 756.00 m of 0.68% CuEq¹ from 965.00 m depth
      • Including 88.00 m of 0.84% CuEq¹ from 1,211.00 m depth

ALD-26-266

• 918.80 m of 0.62% CuEq¹ from 59.00 m depth
  • Including 87.00 m of 0.88% CuEq¹ from 59.00 m depth
  • And 302.00 m of 0.76% CuEq¹ from 422.00 m depth
    • Including 212.00 m of 0.83% CuEq¹ from 490.00 m depth

ALD-26-265

• 901.00 m of 0.47% CuEq¹ from 249 m depth
  • Including 781.00 m of 0.52% CuEq¹ from 296.00 m depth
    • Including 196.00 m of 0.73% CuEq¹ from 516.00 m depth

ALD-26-269

• 940.70 m of 0.49% CuEq¹ from 63.00 m depth
  • Including 165.00 m of 0.80% CuEq¹ from 533.00 m depth
  • And 227.00 m of 0.60% CuEq¹ from 771.00 m depth

ALD-26-271

• 841.90 m of 0.54% CuEq¹ from 193.00 m depth
  • Including 253.00 m of 0.73% CuEq¹ from 722.00 m depth

¹ For individual assays for all metals, see Table 1

John Black, Chief Executive Officer of Aldebaran, commented: “A mineralized interval exceeding 1.7 kilometres in a single drill hole underscores the immense scale of the Altar system. As we move toward our updated mineral resource estimate, we will be incorporating more than 40,000 m of drilling completed at the main Altar deposit since the last resource estimate in late 2024, as well as approximately 30,000 m of drilling completed at the adjacent Radio Porphyry target. Radio Porphyry has never been included in a mineral resource estimate, making this an important milestone for the project. We believe the 2026 resource update will better demonstrate the scale and growth potential of the broader Altar Project and position us well for the Pre-Feasibility Study scheduled for completion in 2027.”

Kevin B. Heather, Chief Geological Officer of Aldebaran, commented: “With the release of this final batch of drill hole results, the Altar project continues to amaze us with long continuous intervals of copper mineralization. The 2025-2026 drilling campaign results have exceeded our expectations, and while we were waiting on these final results to arrive, we have been busy refining and improving our geological and geotechnical models based on this recent drilling. Collectively this bodes well for the upcoming mineral resource estimate and the pre-feasibility study.”

Table 1 below shows detailed assays for all thirteen holes. Figure 1 displays a plan map of the completed drill hole locations, while Figures 2 to 11 display cross sections of the holes reported herein.

Table 1 – Altar Drill Hole Results
	From (m)	To (m)	Interval (m)	Cu (%)	Au (g/t)	Ag (g/t)	Mo (ppm)	As (ppm)	CuEq (%)
ALD-26-260- Total Depth – 1,869.9 m
Interval	141.00	1,869.90	1,728.90	0.41	0.03	1.34	123	81	0.45
Incl.	442.00	1,869.90	1,427.90	0.47	0.03	1.49	143	87	0.52
Incl.	965.00	1,721.00	756.00	0.61	0.03	2.12	197	76	0.68
Incl.	1,211.00	1,299.00	88.00	0.76	0.05	1.87	232	69	0.84
ALD-26-265 – Total Depth – 1,150.00 m
Interval	249.00	1,150.00	901.00	0.41	0.15	1.21	15	183	0.47
Incl.	296.00	1,077.00	781.00	0.45	0.17	1.29	15	196	0.52
Incl.	516.00	712.00	196.00	0.61	0.30	1.64	12	171	0.73
Incl.	619.00	677.00	58.00	0.72	0.42	2.06	8	218	0.87
And	740.00	824.00	84.00	0.52	0.18	1.51	6	382	0.59
And	866.00	945.20	79.20	0.60	0.17	1.58	19	327	0.67
ALD-26-266 – Total Depth -977.80 m
Interval	59.00	977.80	918.80	0.58	0.09	1.58	14	275	0.62
Incl.	59.00	146.00	87.00	0.82	0.13	1.94	13	446	0.88
Incl.	61.00	126.00	65.00	0.90	0.15	2.18	13	591	0.96
And	422.00	724.00	302.00	0.70	0.14	1.11	11	51	0.76
Incl.	490.00	702.00	212.00	0.77	0.16	1.20	8	59	0.83
ALD-26-268 – Total Depth – 550.00 m
Interval	36.00	231.00	195.00	0.24	0.04	1.23	25	362	0.26
ALD-26-269 – Total Depth -1,003.70 m
Interval	63.00	1,003.70	940.70	0.42	0.16	1.37	22	212	0.49
Incl.	533.00	698.00	165.00	0.68	0.31	1.85	13	260	0.80
Incl.	771.00	998.00	227.00	0.53	0.16	2.33	13	383	0.60
ALD-26-270 – Total Depth – 525.00 m
No Reportable Intervals
ALD-26-271 – Total Depth – 1,034.90 m
Interval	193.00	1,034.90	841.90	0.50	0.08	1.02	31	116	0.54
Incl.	722.00	975.00	253.00	0.69	0.07	0.91	31	40	0.73
Incl.	732.00	781.00	49.00	0.77	0.14	1.20	13	106	0.83
ALD-26-272 – Total Depth – 350.00 m
No Reportable Intervals
ALD-26-273 – Total Depth – 435.00 m
No Reportable Intervals
ALD-26-274 – Total Depth – 521.00 m
Interval	114.00	169.00	55.00	0.18	0.03	0.61	5	291	0.19
ALD-26-275 – Total Depth – 360.00 m
No Reportable Intervals
ALD-26-276 – Total Depth – 416.20 m
Interval	321.00	416.20	95.20	0.13	0.33	0.64	22	567	0.25
ALD-26-277 – Total Depth – 230.00 m
Interval	118.00	230.00	112.00	0.13	0.07	1.48	11	459	0.17
The grades are uncut. CuEq values were calculated using copper, gold, silver, and molybdenum. Metal prices utilized for the calculations are Cu = US$3.00/lb, Au = US$1,400/oz, Ag = US$18/oz, and Mo = US$10/lb. Recoveries used for the supporting metals found in the CuEq equation are as follows: Au = 50%, Ag = 51%, (based on historical metallurgical test work) and Mo = 70% (benchmarking from similar deposits). The formula utilized to calculate equivalent values is CuEq % = Cu % + (Au g/t * 0.34025) + (Ag g/t * 0.00446) + (Mo ppm * 0.00023). Intervals represent true thickness of the deposit.

Qualified Person

The scientific and technical data contained in this news release has been reviewed and approved by Dr. Kevin B. Heather, B.Sc. (Hons), M.Sc, Ph.D, FAusIMM, FGS, Chief Geological Officer and director of Aldebaran, who serves as the qualified person (QP) under the definitions of National Instrument 43-101.

ON BEHALF OF THE ALDEBARAN BOARD

(signed) “John Black”

John Black, Chief Executive Officer and Director
Tel: +1 (604) 685-6800
Email: info@aldebaranresources.com

Please click here and subscribe to receive future news releases: https://aldebaranresources.com/contact/subscribe/

For further information, please consult our website at www.aldebaranresources.com or contact:

Ben Cherrington
Manager, Investor Relations
Phone: +44 7538 244 208
Email: ben.cherrington@aldebaranresources.com

About Aldebaran Resources Inc. 

Aldebaran is a mineral exploration company that was spun out of Regulus Resources Inc. in 2018 and has the same core management team. Aldebaran holds an 80% interest in the Altar copper-gold project in San Juan Province, Argentina. The Altar project hosts multiple porphyry copper-gold deposits with potential for additional discoveries. Altar forms part of a cluster of world-class porphyry copper deposits which includes Los Pelambres (Antofagasta Minerals), El Pachón (Glencore), and Los Azules (McEwen Copper). In November 2024, the Company announced an updated mineral resource estimate for Altar, prepared by Independent Mining Consultants Inc. and based on the drilling completed up to and including the 2023-24 field season (independent technical report prepared by Independent Mining Consultants Inc., Tucson, Arizona, titled “Technical Report, Estimated Mineral Resources, Altar Project, San Juan Province, Argentina“, dated December 31, 2024 – see news release dated November 25, 2024). In October 2025 the Company announced a Preliminary Economic Assessment (PEA) for the Altar Project (independent technical report prepared by SRK Consulting Inc, Denver, Colorado, titled “NI 43-101 Technical Report Preliminary Economic Assessment Altar Project San Juan, Argentina”, dated September 30, 2025 – see news release dated October 30, 2025).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sampling and Analytical Procedures

Altar follows systematic and rigorous sampling and analytical protocols which meet and exceed industry standards. These protocols are summarized below and are available on the Aldebaran website at www.aldebaranresources.com.
All drill holes are diamond core holes with PQ, HQ or NQ core diameters. Drill core is collected at the drill site where recovery and RQD (Rock Quality Designation) measurements are taken before the core is boxed and transported to the Altar camp facilities, a short distance away, where the whole core is photographed under more optimum lighting conditions and geological quick log is produced. The whole-core is then marked and sampled into geological defined, systematic 1- to 2-metre sample intervals, unless the geologist determines the presence of an important geological contact, which should not be crossed. The whole-core is then cut-in-half with a diamond saw blade, with half the sample retained in the core box for future reference and the other half placed into a pre-labelled plastic bag, sealed with a two plastic security zip ties, and labeled with a unique sample number. The bagged samples are then placed into larger plastic sacks, and those sacks are sealed with another plastic security zip tie and labelled for shipment. The sacks are then placed onto wooden pallets and wrapped in plastic shrink-wrap and stored in a secure area pending shipment to a certified ALS laboratory sample preparation facility located in Mendoza, Argentina, where the samples are dried, crushed, and pulverized. The resulting sample pulps are sent by batch to the ALS laboratory in Lima for geochemical assay analysis, including a 30g fire assay with an atomic absorption (AA) finish analysis for gold and a full multi-acid digestion (4-acid) with ICP-AES analysis for other elements. Samples with results that exceed maximum detection values for gold are re-analyzed by fire assay with a gravimetric finish and other elements of interest are re-analyzed using precise ore-grade ICP analytical techniques. Aldebaran independently inserts certified control standards (Super Certified Reference Materials (SCRM’s), coarse field blanks, and duplicates into the sample stream to monitor data quality. These control samples represent 10-12% of the total samples submitted and are inserted “blindly” to the laboratory in the sample sequence prior to departure from the Aldebaran facilities. 

Forward-Looking Statements

Certain statements regarding Aldebaran, including management’s assessment of future-plans and operations, may constitute forward-looking statements under applicable securities laws and necessarily involve known and unknown risks and uncertainties, most of which are beyond Aldebaran’s control. Often, but not always, forward-looking statements or information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate” or “believes” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.

Specifically, and without limitation, all statements included in this press release that address activities, events or developments that Aldebaran expects or anticipates will or may occur in the future, including the proposed exploration and development of the Altar project described herein, and management’s assessment of future plans and operations and statements with respect to the completion of the anticipated exploration and development programs, the mineral resource estimate and pre-feasibility study, may constitute forward-looking statements under applicable securities laws and necessarily involve known and unknown risks and uncertainties, most of which are beyond Aldebaran’s control. These risks may cause actual financial and operating results, performance, levels of activity and achievements to differ materially from those expressed in, or implied by, such forward-looking statements. Although Aldebaran believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The forward-looking statements contained in this press release are made as of the date hereof and Aldebaran does not undertake any obligation to publicly update or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities law.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/78f75527-61e5-406d-bffd-056750d3a021

https://www.globenewswire.com/NewsRoom/AttachmentNg/44c72e03-9da5-40c1-9f57-38ca8757ae9c

https://www.globenewswire.com/NewsRoom/AttachmentNg/afb08212-0c01-4b0b-832e-854f02effe5f

https://www.globenewswire.com/NewsRoom/AttachmentNg/c8c2495f-e8ee-4080-b07c-119dbccbf390

https://www.globenewswire.com/NewsRoom/AttachmentNg/8ceeade0-7019-440f-b136-17392acf9cd7

https://www.globenewswire.com/NewsRoom/AttachmentNg/331c161f-06e4-4e58-8312-7a6998db1c3f

https://www.globenewswire.com/NewsRoom/AttachmentNg/20de505d-8480-42aa-8a6a-bdab8dc00e7c

https://www.globenewswire.com/NewsRoom/AttachmentNg/049290ef-1d65-4620-b25a-1bf258d8fb67

https://www.globenewswire.com/NewsRoom/AttachmentNg/5231d064-ae30-4cb5-a68e-de559f892153

https://www.globenewswire.com/NewsRoom/AttachmentNg/a568c772-1747-4601-9655-3a1eb127bc9b

https://www.globenewswire.com/NewsRoom/AttachmentNg/22419fb2-84da-44e2-bed5-419ffda68122

Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,747,245, entitled “AP2 associated kinase 1 inhibitors and uses thereof.” The patent includes composition of matter claims covering forazapadin, Satellos’ lead clinical-stage drug candidate, as well as a broader class of AAK1 inhibitors and related compounds within the company’s muscle regeneration platform.

The composition of matter patent provides intellectual property protection through Sept. 6, 2044. In addition, the company may be eligible for a Patent Term Extension for forazapadin following future U.S. marketing approval, potentially extending patent protection beyond the current expiration date.

“The issuance of this composition of matter patent represents a significant advancement for Satellos and supports our long-term development and commercialization strategy for the program,” said Frank Gleeson, co-founder and chief executive officer of Satellos. “As the strongest form of patent protection for a pharmaceutical product, this patent reinforces the novelty of our approach to restoring muscle regeneration and strengthens our intellectual property (IP) estate surrounding forazapadin. We intend to continue to build on this foundational IP as we advance forazapadin in Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD) and other degenerative muscle diseases.”

Following potential U.S. marketing approval of forazapadin, the company intends to seek to have this patent listed in the Food and Drug Administration’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

ABOUT FORAZAPADIN
Forazapadin is a proprietary, oral, small molecule drug candidate being developed by Satellos as a novel approach to regenerating skeletal muscle lost in degenerative muscle diseases or injury conditions. Forazapadin targets AAK1, a key protein identified by Satellos as believed to be capable of helping restore the body’s natural muscle repair and regeneration biology, a fundamental process that is disrupted in DMD, FSHD and other degenerative conditions. By inhibiting AAK1, forazapadin treatment aims to re-establish a biochemical signal believed to be involved in supporting muscle regeneration. Satellos is advancing forazapadin as a potential treatment for DMD that is independent of dystrophin and applicable regardless of exon mutation status as either a stand-alone or adjunctive therapy, with ongoing Phase 2 clinical studies including BASECAMP, a global, randomized, placebo-controlled study in pediatric participants, and TRAILHEAD, an open-label study in adult participants. A Phase 2 clinical study to evaluate the safety, efficacy and tolerability of forazapadin in adults with FSHD is expected to begin in the fourth quarter of 2026.

ABOUT SATELLOS BIOSCIENCE INC.
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed forazapadin, an orally administered small molecule AAK1 inhibitor designed to address deficits in muscle repair and regeneration. Forazapadin is being evaluated as a potential disease-modifying treatment for DMD in two Phase 2 clinical trials, BASECAMP in pediatric participants with DMD and TRAILHEAD in adults living with DMD. An Investigational New Drug (IND) application to initiate clinical research into forazapadin for the treatment of FSHD has also been cleared. The company has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit www.satellos.com and connect with Satellos on X, LinkedIn, Facebook and Instagram.

NOTICE ON FORWARD-LOOKING STATEMENTS
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the possibility of pursuing regulatory approval for forazapadin; the potential eligibility for a Patent Term Extension for forazapadin following future U.S. marketing approval; the company’s intention to seek to have the composition of matter patent listed in the FDA’s Orange Book following potential U.S. marketing approval of forazapadin; anticipated benefits to patients from forazapadin; and the expected timing for the commencement of the Phase 2 clinical study of forazapadin in adults with FSHD. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are “forward-looking information or statements.” Often, but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective”, “assert” or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. These statements are based on assumptions and subject to risks and uncertainties. In making forward-looking statements, the Company has relied on various assumptions, including but not limited to: its ability to obtain future funding on favorable terms, if at all; obtaining positive results in its clinical trials; its ability to obtain necessary regulatory approvals; its ability to arrange for the manufacturing of its product candidates and technologies; and general business, market and economic conditions. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management’s ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks and uncertainties described in more detail in the “Risk Factors” section of Satellos’ Annual Information Form dated March 27, 2026, and amended and restated short form base shelf prospectus dated August 11, 2026 (each of which is located on Satellos’ SEDAR+ profile), and incorporated by reference in Satellos’ Form F-10 filed with the Securities and Exchange Commission on August 11, 2026, and in Satellos’ public filings on EDGAR (sec.gov) and SEDAR+ (sedarplus.ca). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.

CONTACTS
Investors: Caitlin Lowie, Vice President, Investor Relations & Communications, ir@satellos.com
Media: Emily Williams, Senior Director, Communications, media@satellos.com

TALON, D-FLY and Counter-UAS Concepts Designed to Integrate Aerial ISR, Logistics, Strike and Interception with STRATUM Ground and Command Systems; All Programs Remain in Development

WEST HOLLYWOOD, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave” or the “Company”) today highlighted the aerial and counter-unmanned aircraft system (“counter-UAS”) layer of its developing autonomous defense ecosystem.

VisionWave’s aerial architecture is being designed to support tactical intelligence, surveillance and reconnaissance (“ISR”), logistics, strike, counter-UAS and other mission applications, while interoperating with the Company’s STRATUM ground platforms and command architecture. 

The Company’s currently contemplated aerial development programs, none of which is in production, commercially available or the subject of a customer order, include:

TALON 10 — tactical ISR and surveillance;

TALON HEAVY LIFT 40 — aerial logistics;

TALON 10 STRIKE — FPV strike configuration;

TALON GUARDIAN — two-stage payload-release architecture;

TALON SHOOTER — gimbaled precision-support configuration; and

D-FLY and counter-UAS concepts — designed around autonomous interception and layered counter-UAS response.

“We believe modern autonomous operations increasingly require ground vehicles, aerial platforms, sensors and counter-UAS systems to operate from the same intelligence picture,” said Douglas Davis, Chief Executive Officer and Executive Chairman of VisionWave. “Our development strategy is focused on creating that interoperability from the outset.”

One Mission Picture

VisionWave’s architecture is intended to allow aerial assets to launch from or operate alongside ground elements, perform missions and share information through a common operating environment.

The Company ultimately intends for ground and aerial systems to be tasked through one mission picture and one operator control architecture. 

Pursuing Counter-UAS Opportunities

VisionWave is pursuing opportunities in counter-UAS and related defense markets in the United States and internationally. The Company has submitted proposals in response to U.S. Government counter-UAS solicitations. No award has been made to the Company, and there can be no assurance that any proposal will result in an award. The Company is also engaged in preliminary, non-binding discussions with a European defense ministry regarding a possible counter-UAS interceptor trial. No agreement has been reached, no terms have been agreed, and there can be no assurance that any trial, contract or order will result.  

“Our strategy is to build beyond the interceptor itself,” Davis added. “Detection, classification, decision support, autonomous platforms and effectors ultimately need to function together. That is the architecture we are pursuing.”

The systems and capabilities described herein are under development or exist only as concepts. None is in production or commercially available, none has generated revenue, and none should be understood as a commercially deployed capability. Their development, testing, demonstration, export and sale are subject to regulatory, export-authorization and procurement requirements, and there can be no assurance that any of them will be completed, will achieve their intended performance or will result in a customer order.

ABOUT VISIONWAVE

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense and advanced sensing technology company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave’s mission is to connect defense innovation with civilian progress through shared core technologies intended for use across air, land and fixed-site environments. The Company’s website is https://www.vwav.inc. Information contained on, or accessible through, the Company’s website is not incorporated by reference into, and does not form a part of, this press release or any filing of the Company with the Securities and Exchange Commission. Certain of the platforms, payloads, sensing technologies and software described in this press release are in development, have not completed testing or qualification, are not commercially available and have not generated material revenue.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are generally identified by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “forecast,” “predict,” “target,” “objective,” “strategy,” “designed to,” “intended to,” “concept,” “under development” and similar expressions, or by statements that events or trends “may,” “will,” or “could” occur. Forward-looking statements in this press release include, without limitation, statements regarding the intended design, capabilities and mission applications of the TALON family, D-FLY and the Company’s counter-UAS concepts; the intended interoperability of aerial and ground systems through a common command architecture; the outcome of proposals submitted in response to U.S. Government solicitations; and the outcome of preliminary discussions regarding a potential counter-UAS interceptor trial.

Forward-looking statements are not guarantees of future performance, are based on management’s current expectations and assumptions as of the date of this press release, and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied, including, but not limited to: the fact that substantially all of the platforms, payloads, sensing technologies and software described in this press release are in development, have not completed testing, qualification or independent third-party validation, are not commercially available, have not generated material revenue, and may never be completed, certified, produced at scale or adopted by any customer; the Company’s need to raise substantial additional capital to fund development and its ability to do so on acceptable terms or at all; the substantial dilution to existing stockholders resulting from sales of common stock under the Company’s at-the-market offering programs, conversions of the Company’s outstanding convertible debentures, exercises of outstanding warrants and shares issuable as consideration in acquisitions and strategic transactions; the Company’s history of operating losses, accumulated deficit and working capital deficiency, and the substantial doubt regarding the Company’s ability to continue as a going concern described in its most recent periodic report; the Company’s ability to satisfy the continued listing standards of The Nasdaq Stock Market, including the minimum bid price requirement, and the anticipated effects of the reverse stock split approved by the Company’s stockholders; the Company’s dependence on government procurement processes, competitive solicitations, budget appropriations and program funding, none of which has resulted in an award, contract or order to the Company; the risks of pursuing sales to foreign governments and foreign defense ministries, including procurement delays, offset requirements, political and geopolitical developments and the absence of any binding commitment; U.S. and non-U.S. export control, licensing, technology transfer, defense trade registration and economic sanctions requirements applicable to the technologies described in this press release, including the International Traffic in Arms Regulations and the Export Administration Regulations, and the risk that required authorizations are delayed, conditioned or denied; the Company’s ability to obtain, protect and enforce intellectual property rights and the risk that pending patent applications do not issue; risks relating to acquisitions, integration and reliance on third parties, partners, suppliers and subcontractors; and the other risks and uncertainties described under “Risk Factors” in the Company’s Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission.

All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release and in the Company’s SEC filings. VisionWave undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements.

Contact for Investors: investors@vwav.inc

The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities 

On track to report topline results for the Phase 3 upLIFT study in tumor HI this quarter

REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (“HI”), today announced that following a preliminary review of detailed data from the Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia due to congenital HI, the U.S. Food and Drug Administration (“FDA” or “Agency”) recommended a pre-BLA meeting with the Company as a precursor to submitting a BLA.

As previously reported, sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI, demonstrated glycemic improvements, but did not meet the primary endpoint because the reductions in hypoglycemia events by finger-stick self-monitored blood glucose (SMBG) were not statistically significant compared to placebo. Although the key secondary endpoint of time in hypoglycemia by continuous glucose monitoring (CGM) was not met in the Week 24 End-of-Treatment evaluable window, consistent and clinically relevant improvements in hypoglycemia were observed for this and multiple other CGM-based hypoglycemia endpoints in both treatment arms.

At a March 2026 Type B meeting with FDA, the Agency acknowledged the challenges posed by behavioral factors in clinical trials in this patient population, including limitations associated with SMBG based measures of hypoglycemia. At the meeting, the Agency requested that the Company provide the continuous CGM data for its independent review. In June 2026, the Company submitted source and analysis datasets, and summary results from a substantial number of pre-specified, post-hoc, and sensitivity analyses.

The Agency has reviewed the data and, despite the trial’s failure to meet the prespecified primary and key secondary endpoints, as a next step, encouraged the Company to request a Type B pre-BLA meeting as a precursor to submitting a BLA for congenital HI. The Agency explicitly did not opine on the approvability of ersodetug for congenital HI and noted that any such determination would only be made as a part of an in-depth evaluation of the supporting data during a formal BLA review, as is customary during a BLA process.

In light of expected topline results this quarter from the Company’s upLIFT study in tumor HI and the potential for an additional pre-BLA meeting for that indication should the study results support a submission, the Company will evaluate its overall BLA submission strategy for potentially both programs following the announcement of upLIFT study results.

“We appreciate FDA’s thorough review of the extensive body of data generated in sunRIZE and are encouraged by the Agency’s recognition that this data will require in-depth evaluation during a formal BLA review,” said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. “We share FDA’s commitment to addressing the significant unmet needs of individuals living with rare diseases like congenital HI, where traditional drug development can present unique challenges. We believe this unusual process of preliminary review of detailed data demonstrates what can be achieved when regulators, companies, clinicians, and advocacy organizations work collaboratively to evaluate the totality of evidence for promising rare disease therapies.”

“For many people living with congenital hyperinsulinism, the threat of severe and unpredictable hypoglycemia remains a daily reality, and existing treatments are not enough,” said Julie Raskin, Chief Executive Officer of Congenital Hyperinsulinism International (CHI). “We are encouraged by the progress toward potential new therapies and grateful to the patients, families, researchers, clinicians, regulators, and biotechnology companies working together to bring better options to our community.”

The open-label extension (OLE) phase of the study is ongoing, with a continued high retention rate, equating to an ersodetug treatment duration in sunRIZE ranging from approximately nine months to well over two years. This, along with continued glycemic control and a notable reduction in the use of background standard of care therapies, potentially indicate continued glycemic and clinical benefit with ersodetug in longer-term use.

About Ersodetug 

Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from pancreatic insulin or paraneoplastic IGF-2 secretion and from entero-incretin pathways, it has the potential to be universally effective at treating refractory hypoglycemia due to any form of hyperinsulinism (HI), including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric/non-bariatric gastrointestinal surgery hypoglycemia. Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority.

About Rezolute, Inc. 

Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.

Forward-Looking Statements  

This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. These forward-looking statements include, but are not limited to, the overall BLA process, the potential efficacy of ersodetug in treating hypoglycemia as well as our ability to complete enrollment of the upLIFT study this year and announce topline results. Our ability to predict results or our plans or strategies is inherently uncertain. Notably, despite the FDA encouraging us to request a pre-BLA meeting for congenital HI, there can be no assurance that FDA will agree with the Company that the totality of evidence from the sunRIZE program demonstrates a clinically meaningful benefit or is sufficient to support the approval for ersodetug in congenital HI. Accordingly, FDA may determine that additional clinical data, including data from a new randomized controlled trial similar to sunRIZE, are required to support approval. Should the Agency make such a determination, it would adversely impact the timing and feasibility of approval for the congenital HI indication as well as the the commercial potential for ersodetug. Actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. 

Contacts: 

Christen Baglaneas
Rezolute, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
Rezolute, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
cmkim@rezolutebio.com
336-608-9706

Tsang joins AIBotics as Strategic Advisor ahead of contemplated CEO and director appointment upon closing, as Company moves to acquire the U.S.-focused Empulser defense-technology platform

MIAMI, Oct. 05, 2026 (GLOBE NEWSWIRE) — AIBotics, Inc. (OTCID: AIBT) (“AIBotics” or the “Company”), a public company focused on AI-enabled robotics, intelligent automation and emerging technology, today announced that on October 2, 2026 it entered into an Agreement for the Exchange of Stock (the “Exchange Agreement”) with Empulser Enterprises LLC (“Empulser”), a Wyoming limited liability company founded by Patrick Tsang, and the members of Empulser. Upon closing, AIBotics will acquire 100% of the issued and outstanding membership interests of Empulser, and Empulser will become a wholly owned subsidiary of AIBotics. In connection with the transaction and the Company’s next phase of strategic growth, Tsang has joined AIBotics as a Strategic Advisor.

The agreement brings Tsang and Empulser to the center of AIBotics’ evolving public-company strategy. Empulser is being developed around the convergence of wireless power, autonomous systems, AI-enabled unmanned technologies and the infrastructure required to support more persistent autonomous operations. The proposed acquisition is intended to provide a public-market platform through which Empulser can pursue technology development, intellectual-property expansion, testing and validation, capitalization, strategic relationships and, ultimately, commercial and defense applications.

Patrick Tsang Brings a New Technology Platform to AIBotics

Tsang brings more than two decades of experience across global capital markets, public-company transactions, mergers and acquisitions, strategic investing, corporate development and emerging technology. As Strategic Advisor to AIBotics, he is expected to work with Chief Executive Officer Ben Kaplan and the Company on strategic growth, capital-markets strategy, corporate development, international partnerships and the identification of opportunities across AI, robotics, autonomous systems and related technologies.

Tsang is Chairman of Tsang Group, a fourth-generation single family office with interests across technology, real estate and natural resources. Over more than two decades, he has worked across international investment, capital formation, mergers and acquisitions, corporate development and emerging technology, building relationships across Asia, Europe, the Middle East and North America. He is also the Founder and Chief Executive Officer of Empulser, the defense and dual-use technology platform that AIBotics has agreed to acquire.

A Public-Market Track Record

Under Patrick Tsang’s leadership, an early-stage investment was made in Pulse Evolution Group in 2018, alongside a strategic advisory role. Pulse subsequently became part of FaceBank Group, which completed its merger with fuboTV in 2020, culminating in fuboTV trading on the New York Stock Exchange during the Covid period.

Empulser: Defense, Autonomy and the Infrastructure Behind Intelligent Machines

Empulser is focused on building a U.S. defense and dual-use technology platform around wireless power and autonomous systems. Its development strategy centers on technologies intended to address a fundamental challenge facing unmanned platforms: extending operational endurance while reducing dependence on manual charging and support infrastructure. Empulser’s broader vision includes wireless power transfer, autonomous aerial and ground systems, AI-enabled mission functionality and infrastructure designed to support unmanned operations across defense, government, critical-infrastructure and commercial environments.

Empulser remains in a development and commercialization phase. Future technology, product, testing, certification, customer and revenue milestones will be announced only as they are achieved and can be substantiated. AIBotics and Empulser intend to build public communications around documented execution rather than projected milestones.

Transaction Overview

Under the Exchange Agreement, AIBotics will acquire 100% of the issued and outstanding membership interests of Empulser from the Empulser Members in exchange for up to 2,200,000 shares of a newly designated Series C Preferred Stock having an aggregate stated value of up to $22.0 million. The Certificate of Designation provides for an original issue price of $10.00 per share. Of the total acquisition consideration, 220,000 shares, representing 10%, are allocated to the closing and 198,000, representing 9%, shares are allocated to each of ten separate earn-out milestones.

The earn-out period begins at closing and continues for 36 months. The milestones cover specified patent filings and issuances, product demonstration and flight testing, acceptance into a formal test, evaluation or pilot program, and achievement of $500,000 in cumulative recognized revenue. Shares tied to a milestone are earned only if that milestone is achieved during the earn-out period; unearned milestone shares will cease to be issuable or will be forfeited and cancelled, as applicable under the Exchange Agreement.

The Series C Preferred Stock pays no dividends and generally has no voting rights except as provided in the Certificate of Designation or required by law. Each share is convertible at the holder’s option into AIBotics common stock under the formula set forth in the Certificate of Designation. The initial conversion price will equal the closing price of AIBotics common stock on its principal market on the trading day immediately preceding the transaction closing, subject to specified adjustments. Conversion is subject to certain beneficial-ownership limitations, subject to the notice and waiver provisions described in the Certificate of Designation.

AIBotics may, in its sole discretion, advance up to $2.0 million to Empulser before closing for expenditures under an approved budget. Any advances will be structured as loans secured by a first-priority security interest in all of Empulser’s assets and will be subject to the promissory note and related security documents to be negotiated.

Closing is subject to customary and transaction-specific conditions, including the transfer of 100% of Empulser’s membership interests, compliance with the parties’ covenants and representations, delivery by Empulser of audited financial statements for the periods required by Regulation S-X prepared in accordance with U.S. GAAP, and AIBotics being current in its SEC and/or OTC Markets filing obligations and labeled “Current” on OTC Markets. The Exchange Agreement provides for termination in specified circumstances if the transaction has not closed within 90 days after October 2, 2026 or if applicable closing conditions have not been satisfied or waived by January 2, 2027. There can be no assurance that the transaction will close.

As disclosed in the Form 8-K, Tsang is to provide consulting and advisory services regarding AIBotics’ existing business for 90 days or until a chief executive officer agreement becomes effective. Subject to applicable law, a satisfactory background and eligibility review, approval by AIBotics’ Board of Directors in the exercise of its fiduciary duties, and execution of a satisfactory CEO agreement, AIBotics intends to appoint Tsang as Chief Executive Officer and a director effective upon closing of the Empulser acquisition.

The foregoing is a summary of selected transaction terms. Additional information regarding the Exchange Agreement, the Series C Preferred Stock, the closing conditions and the proposed transaction is contained in AIBotics’ Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission, including the Exchange Agreement filed as Exhibit 10.1. The full agreement and filed disclosure should be reviewed for a complete description of the transaction.

Management Commentary

Ben Kaplan, Chief Executive Officer of AIBotics, said, “This is an important step in the evolution of AIBotics. Patrick brings a rare combination of global capital-markets experience, public-company transaction expertise, technology investing, corporate development and international relationships — and he has built Empulser around technologies that fit directly into where we believe AI and autonomous systems are heading. The definitive agreement gives us a potential foundation for building a much broader defense and dual-use technology platform. Patrick’s experience identifying emerging opportunities, attracting capital, developing strategic relationships and navigating public markets can be extremely valuable as we move into this next phase.”

Patrick Tsang said, “This transaction marks an important new chapter for Empulser. We believe the opportunity in autonomous systems is much broader than building another drone or robot. The real challenge is enabling intelligent machines to operate for longer, with greater resilience and less human intervention. Empulser is being built around that challenge — combining wireless power, autonomous systems and enabling technologies to increase the persistence and effectiveness of unmanned platforms. Working with Ben and the AIBotics team gives us a public-market platform from which to develop the technology, attract world-class partners and capital, and build a significant U.S. defense and dual-use technology company.”

During the pre-closing period, Tsang’s advisory role is expected to include strategic growth, capital formation, public-market strategy, corporate development, international partnerships and the evaluation of complementary emerging technologies and acquisition opportunities. As disclosed in the Form 8-K, following the closing of the acquisition of Empulser, AIBotics also intends, subject to the conditions described in the Exchange Agreement, to appoint Tsang as Chief Executive Officer and a director. The Company expects to provide additional updates as the Empulser transaction progresses and as material operating milestones are achieved.

About AIBotics

AIBotics, Inc. is a global technology company building a platform around AI-enabled robotics, autonomous systems and intelligent automation. The Company focuses on applying advanced technologies to real-world environments through strategic partnerships, technology development and international market relationships. AIBotics seeks to identify, develop, implement and scale solutions that improve how machines operate, automate business processes and extend the practical application of artificial intelligence into the physical world. Through a scalable, partnership-driven model, AIBotics is building a diversified robotics and autonomous-systems platform designed to support commercial, industrial and other mission-driven applications across global markets. For more information on AIBotics, visit www.aibotics.ai

About Empulser Enterprises LLC

Empulser Enterprises LLC is a U.S.-focused defense and dual-use technology company developing a platform around wireless power, autonomous systems, unmanned technologies and supporting infrastructure. Empulser’s development strategy is focused on technologies intended to improve the endurance, deployment and coordination of autonomous platforms across defense, government, critical-infrastructure and commercial applications. Empulser’s products and technologies are in development, and future milestones are subject to successful engineering, testing, validation, certification, funding and commercialization. For more information on Empulser, visit www.empulser.com.

About Patrick Tsang

Patrick Tsang is an international investor and entrepreneur and Chairman of Tsang Group, a fourth-generation single family office with interests across technology, real estate and natural resources. He is the Founder and Chief Executive Officer of Empulser Enterprises LLC, a U.S.-focused defense and dual-use technology company developing technologies around wireless power, autonomous systems and unmanned platforms.

Over more than two decades, Tsang has worked across international investment, capital formation, mergers and acquisitions, corporate development and emerging technology, building relationships across Asia, Europe, the Middle East and North America. Through his leadership, he was an early-stage investor and strategic advisor to Pulse Evolution, helping guide its journey through the FaceBank/fuboTV transaction to fuboTV’s listing on the New York Stock Exchange during the Covid period. SEC filings subsequently referenced an approximately 300-times return in two years on the investment based on fuboTV’s late-2020 share price.

Tsang is a qualified solicitor in England and Wales and Hong Kong and attended Harvard Business School’s Owner/President Management (OPM) program. He is the author of The Global Citizen and has been actively involved in philanthropy and international leadership throughout his career, including through the Duke of Edinburgh’s World Fellowship, Rotary International and YPO. He was recognized as China Economic Person of the Year during the China Economic Development Forum in 2014.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements include, among other things, statements regarding the proposed acquisition of Empulser; the anticipated structure, timing, closing and benefits of the transaction; the issuance, earning and conversion of Series C Preferred Stock and potential dilution associated with conversion; the achievement and verification of earn-out milestones; any discretionary pre-closing loans by AIBotics to Empulser; the contemplated management transition involving Patrick Tsang; AIBotics’ and Empulser’s business strategies; technology development, testing, validation, certification and commercialization; intellectual-property development; financing and capital formation; strategic partnerships; government, defense and commercial opportunities; potential customers, contracts and revenue; future acquisitions; and the Company’s broader strategy in AI, robotics, autonomous systems and defense and dual-use technology. Forward-looking statements are based on current expectations, assumptions and estimates and are subject to risks and uncertainties that could cause actual results to differ materially. These risks include, among others, the possibility that the transaction may not close on the anticipated terms or timing, or at all; failure to satisfy or waive closing conditions, including delivery of required audited financial statements and maintenance of required filing status; termination following due diligence, an uncured material breach or a material adverse change; AIBotics’ decision not to provide discretionary pre-closing financing or the parties’ failure to execute satisfactory loan and security documents; failure to achieve or substantiate earn-out milestones; setoff or cancellation of earn-out consideration; dilution associated with conversion of preferred stock; failure to satisfy the conditions to Patrick Tsang’s proposed appointment as Chief Executive Officer and a director; integration risks; development and engineering risks; testing, certification and regulatory requirements; protection of intellectual property; competition; dependence on key personnel and strategic relationships; customer adoption; government procurement processes; and the Company’s ability to execute its business plan. Readers should review AIBotics’ filings with the U.S. Securities and Exchange Commission, including the Current Report on Form 8-K relating to the Exchange Agreement, for additional information concerning risks and uncertainties. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update them except as required by law.

Media and Investor Relations

David Kugelman
Atlanta Capital Partners, LLC
(404) 856-9157 Office
(404) 281-8556 Mobile and WhatsApp
dk@atlcp.com

• An alliance agreement was signed with PDVSA, Lindsayca and Fulcrum LNG, Inc. to restore energy infrastructure for gas production
• An MOU with New Stratus Energy Inc. was also recently signed to support the future development of in-country oil and gas resources

CARACAS, Venezuela, Oct. 05, 2026 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR), an energy technology company, Monday announced the signing of two strategic agreements to accelerate the revitalization of Venezuela’s energy infrastructure across the natural gas value chain and expansion of the country’s energy production.

In Caracas, the company signed a strategic alliance agreement with PDVSA, Lindsayca and Fulcrum LNG, Inc. to revitalize and expand the country’s natural gas infrastructure. Baker Hughes also recently signed a separate Memorandum of Understanding (MOU) with New Stratus Energy Inc. to support the development of future oil and gas prospects.

Together, these agreements establish an enterprise deal framework that can connect upstream resource development, midstream infrastructure, gas monetization, and LNG commercialization. This creates a pathway to unlock Venezuela’s significant natural gas potential.

“A central objective of these partnerships is the development of an integrated gas value chain capable of transforming Venezuela’s substantial natural gas resources into reliable domestic supply and future export opportunities, including the potential to export the first LNG molecules produced in Venezuela,” said Lorenzo Simonelli, chairman and CEO of Baker Hughes. “Venezuela holds tremendous potential to become a significant contributor to the evolving global energy landscape, and these agreements are designed to bring world-class resource opportunities, project development, energy infrastructure & technologies, and financing expertise together to realize this.”

“This strategic alliance with PDVSA is a historic opportunity to maximize the use and value of Venezuela’s natural gas resources, and it reflects the capabilities and expertise of Fulcrum, Lindsayca and Baker Hughes in developing fully integrated gas value chains, from upstream production to end markets,” said Jesus Bronchalo, CEO of Fulcrum LNG, Inc.

“In the near term, we will work closely with PDVSA to identify and execute the infrastructure developments and upgrades needed to meet its internal gas requirements, while pursuing opportunities to supply natural gas to the domestic market to support reliable power generation for Venezuela and its people. Over the medium and long term, we will evaluate the development and financing of new open-access midstream and LNG infrastructure that gives PDVSA and other upstream operators solutions to monetize their gas, positioning Venezuela to become a key player in the global gas and LNG industry and helping meet growing world energy demand,” Bronchalo said.

About the agreements

Under the alliance with PDVSA, Lindsayca and Fulcrum, the companies will combine Baker Hughes’ broad portfolio of industrialized energy solutions for oil and gas field development, gas infrastructure and LNG solutions, Lindsayca’s engineering, procurement, construction, and operational capabilities, and Fulcrum’s midstream and LNG project development, financing and market access. The collaboration will focus on developing project specific agreements, advancing critical infrastructure required to process, transport, commercialize, and export natural gas, for the first time in the history of Venezuela.

The alliance is a cooperation framework. Any specific project will be subject to separate definitive agreements, each party’s internal approvals, and applicable U.S. sanctions and export control requirements, including authorizations issued by the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC).

Through the MOU with New Stratus Energy, Baker Hughes will support the development of future oil and gas prospects. The partnership will leverage Baker Hughes’ integrated portfolio of subsurface, drilling, production, processing, digital, emissions abatement, power generation, oil and gas monetization, and liquefied natural gas (LNG) technologies to maximize resource recovery opportunities and accelerate future project developments.

Baker Hughes has supported Venezuela’s energy sector for more than 60 years. Its installed base in country includes more than 1,200 oil production systems, the largest artificial lift footprint, significant flexible pipe infrastructure, and approximately 240 turbomachinery units across 23 sites.

About Baker Hughes
Baker Hughes (NASDAQ: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and conducting business in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner and more efficient for people and the planet. Visit us at bakerhughes.com.

About Lindsayca Inc.

Lindsayca Inc. is a U.S. company headquartered in Houston, specializing in engineering, procurement, modular fabrication, construction, commissioning, and operation of energy infrastructure. Through Lindsay C.A., established in Venezuela in 1986, it brings four decades of experience developing gas, oil, and power generation projects in the country. Its track record combines international project execution capabilities with knowledge of Venezuela’s operating environment, specialized talent, and local engineering and fabrication resources. In alliance with PDVSA, Baker Hughes, and Fulcrum LNG, Inc., Lindsayca contributes this experience to transform Venezuela’s natural gas potential into productive infrastructure, restore power generation capacity, and strengthen the domestic energy supply. Its participation is focused on developing an integrated value chain that culminates in the production and export of liquefied natural gas (LNG), helps position Venezuela in international markets, and creates jobs, opportunities for domestic suppliers, and development for its communities.

About Fulcrum LNG, Inc.

Fulcrum LNG, Inc. is a U.S.-based independent developer of midstream natural gas and liquefied natural gas (LNG) infrastructure in international markets. Together with its world-class consortium partners, Fulcrum applies the same flexible business model used to develop gas infrastructure on the U.S. Gulf Coast. Fulcrum develops, finances, and operates shared, open-access midstream gas infrastructure, including LNG facilities, with private capital and independently of upstream producers. This approach removes the infrastructure financing burden from host governments and upstream operators, provides alternative gas monetization solutions and greater optionality, and brings more gas to domestic and export markets. Fulcrum has a broad portfolio of opportunities, primarily in Latin America and the Atlantic Basin.

For more information, please contact:

Media Relations
Adrienne M. Lynch
+1 713-906-8407
Adrienne.lynch@bakerhughes.com 

Investor Relations
Chase Mulvehill
+1 346-297-2561
investor.relations@bakerhughes.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/de053a70-43d9-472c-81c7-6721adabfb3d

Agreement with EU-based manufacturer expands TurboGen’s defense and civilian markets and features an initial five-year term with automatic renewals to support ongoing commercial production

PETAH TIKVA, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) — TurboGen Ltd. (NASDAQ:TRBG) (TASE:TURB) (“TurboGen” or the “Company”), a developer of combined heat and power systems based on multifuel microturbines, today announces it has entered into a long-term agreement (“LTA”) with an engineering and manufacturing provider for the serial development and production of the Company’s proprietary 20kW systems. 

“This milestone collaboration marks the transition from prototype development to serial production with a tier-one, EU-based global design and manufacturer. Upon completion of the development phase, we anticipate readiness for commercialization of our compact 20kW systems.” stated Yaron Gilboa, TurboGen’s Chief Executive Officer. “This LTA also aims to support product sales for defense as well as civilian projects and sales. This LTA further demonstrates TurboGen’s dedication toward rapid advancement into serial production and revenue generation.”

The initial period of the LTA will be five years, with automatic annual renewals designed to support ongoing commercial production and demand.

About TurboGen

Founded in response to technologically address the threat of climate change and the lack of grid capacity, TurboGen Ltd. (NASDAQ:TRBG) (TASE:TURB) develops combined heat and power systems based on multifuel microturbines. These microturbines are used for local electricity, energy, and heat production. To learn more, please visit: https://turbogenchp.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, TurboGen is using forward looking statements in this press release when it discusses: its transition from prototype development to serial production; commercialization of its compact 20kW systems; and its dedication towards rapid advancement into serial production and revenue generation. Because such statements deal with future events and are based on TurboGen’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of TurboGen could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2026, as amended, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

IR and Communications Contact:

IR@turbogenchp.com